83 related articles for article (PubMed ID: 16714224)
1. The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.
McCarthy DA; Macey MG; Streetly M; Schey SA; Brown KA
Int Immunopharmacol; 2006 Jul; 6(7):1194-203. PubMed ID: 16714224
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
Schey SA; Fields P; Bartlett JB; Clarke IA; Ashan G; Knight RD; Streetly M; Dalgleish AG
J Clin Oncol; 2004 Aug; 22(16):3269-76. PubMed ID: 15249589
[TBL] [Abstract][Full Text] [Related]
3. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.
Streetly MJ; Gyertson K; Daniel Y; Zeldis JB; Kazmi M; Schey SA
Br J Haematol; 2008 Apr; 141(1):41-51. PubMed ID: 18324965
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of the high-affinity receptor for IgG (FcRI, CD64) on neutrophils in multiple myeloma.
Ohsaka A; Saionji K; Takagi S; Igari J
Hematopathol Mol Hematol; 1996; 10(3):151-60. PubMed ID: 8878733
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil CD64 (FcgammaRI) expression is a specific marker of bacterial infection: a study on the kinetics and the impact of major surgery.
Fjaertoft G; Håkansson LD; Pauksens K; Sisask G; Venge P
Scand J Infect Dis; 2007; 39(6-7):525-35. PubMed ID: 17577814
[TBL] [Abstract][Full Text] [Related]
6. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.
Streetly M; Hunt BJ; Parmar K; Jones R; Zeldis J; Schey S
Eur J Haematol; 2005 Apr; 74(4):293-6. PubMed ID: 15777340
[TBL] [Abstract][Full Text] [Related]
7. Plasma from patients with sepsis up-regulates the expression of CD49d and CD64 on blood neutrophils.
Lewis SM; Treacher DF; Bergmeier L; Brain SD; Chambers DJ; Pearson JD; Brown KA
Am J Respir Cell Mol Biol; 2009 Jun; 40(6):724-32. PubMed ID: 19011162
[TBL] [Abstract][Full Text] [Related]
8. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets.
Bunescu A; Seideman P; Lenkei R; Levin K; Egberg N
J Rheumatol; 2004 Dec; 31(12):2347-55. PubMed ID: 15570633
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro.
Guckian M; Dransfield I; Hay P; Dalgleish AG
Clin Exp Immunol; 2000 Sep; 121(3):472-9. PubMed ID: 10971513
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
13. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
[TBL] [Abstract][Full Text] [Related]
14. Effect of thalidomide on apoptosis of lymphocytes and neutrophils.
Aseffa A; Dietrich MA; Shannon EJ
Immunopharmacol Immunotoxicol; 1997 Aug; 19(3):313-26. PubMed ID: 9248860
[TBL] [Abstract][Full Text] [Related]
15. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
16. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
17. Neutropenia associated with beta-lactam antibiotics.
Kirkwood CF; Smith LL; Rustagi PK; Schentag JJ
Clin Pharm; 1983; 2(6):569-78. PubMed ID: 6653059
[TBL] [Abstract][Full Text] [Related]
18. High expression of neutrophil and monocyte CD64 with simultaneous lack of upregulation of adhesion receptors CD11b, CD162, CD15, CD65 on neutrophils in severe COVID-19.
Karawajczyk M; Douhan Håkansson L; Lipcsey M; Hultström M; Pauksens K; Frithiof R; Larsson A
Ther Adv Infect Dis; 2021; 8():20499361211034065. PubMed ID: 34377464
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide-induced severe neutropenia during treatment of multiple myeloma.
Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y
Int J Hematol; 2004 Apr; 79(3):283-8. PubMed ID: 15168599
[TBL] [Abstract][Full Text] [Related]
20. Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome.
Sridhar S; Dutta TK; Basu D
J Indian Med Assoc; 2011 Dec; 109(12):880-2, 887-8. PubMed ID: 23469567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
